A nomogram for predicting pathological complete response in patients with human epidermal growth factor receptor 2 negative breast cancer

Table 1 Clinicopathologic characteristics of patients

	Overall			Training set			Validation set
	ALL (N)	pCR (N)	pCR rate	ALL (N)	pCR (N)	pCR rate	ALL (N)	pCR (N)	pCR rate
Total	815	111	13.6 %	500	68	13.6 %	315	43	13.7 %
Age
≤40 years	165	28	17.0 %	105	17	16.2 %	60	11	18.3 %
>40 years	650	83	12.8 %	395	51	12.9 %	255	32	12.5 %
Menopausal status
Pre-menopausal	457	65	14.2 %	276	40	14.5 %	181	25	13.8 %
Post-menopausal	358	46	12.8 %	224	28	12.5 %	134	18	13.4 %
Tumor size
T1	89	21	23.6 %	60	15	25.0 %	29	6	20.7 %
T2	346	47	13.6 %	210	30	14.3 %	136	17	12.5 %
T3	235	28	11.9 %	137	15	10.9 %	98	13	13.3 %
T4	145	15	10.3 %	93	8	8.6 %	52	7	13.5 %
Nodal status
N0	170	22	12.9 %	100	15	15.0 %	70	7	10.0 %
N1	593	79	13.3 %	363	45	12.4 %	230	34	14.8 %
N2	23	4	17.4 %	16	3	18.8 %	7	1	14.3 %
N3	29	6	20.7 %	21	5	23.8 %	8	1	12.5 %
Hormone receptor status
Negative	235	54	23.0 %	147	36	24.5 %	88	18	20.5 %
Positive	580	57	9.8 %	353	32	9.1 %	227	25	11.0 %
Regimens
Cyclophosphamide, epirubicin and 5-fluorouracil	107	2	1.9 %	66	1	1.5 %	41	1	2.4 %
Cyclophosphamide, epirubicin and 5-fluorouracil followed by paclitaxel or docetaxel and epirubicin	116	9	7.8 %	73	5	6.8 %	43	4	9.3 %
Navelbine and epirubicin	153	15	9.8 %	94	8	8.5 %	59	7	11.9 %
Paclitaxel and carboplatin or paclitaxel and cisplatin	439	85	19.4 %	267	54	20.2 %	172	31	18.0 %
Cycles
1-2	97	3	3.1 %	61	2	3.3 %	36	1	2.8 %
3-4	578	93	16.1 %	359	58	16.2 %	219	35	16.0 %
5-6	140	15	10.7 %	80	8	10.0 %	60	7	11.7 %

ISSN: 1471-2407